1-19 of 19
Pasi A. Jänne
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer

Yanan Kuang, Andrew Rogers, Beow Y. Yeap, Lilin Wang, Mike Makrigiorgos, Kristi Vetrand, Sara Thiede, Robert J. Distel, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (8): 2630–2636.
https://doi.org/10.1158/1078-0432.CCR-08-2592
Published: 15 April 2009
View article titled, Noninvasive Detection of <em>EGFR</em> T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
Open the PDF for Noninvasive Detection of <em>EGFR</em> T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer in another window
Journal Articles

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Kwok-K. Wong, Paula M. Fracasso, Ronald M. Bukowski, Thomas J. Lynch, Pamela N. Munster, Geoffrey I. Shapiro, Pasi A. Jänne, Joseph P. Eder, Michael J. Naughton, Matthew J. Ellis, Suzanne F. Jones, Tarek Mekhail, Charles Zacharchuk, Jennifer Vermette, Richat Abbas, Susan Quinn, Christine Powell, Howard A. Burris
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2552–2558.
https://doi.org/10.1158/1078-0432.CCR-08-1978
Published: 01 April 2009
View article titled, A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
Open the PDF for A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors in another window
Journal Articles

Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification

Takafumi Okabe, Isamu Okamoto, Sayaka Tsukioka, Junji Uchida, Erina Hatashita, Yuki Yamada, Takeshi Yoshida, Kazuto Nishio, Masahiro Fukuoka, Pasi A. Jänne, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (3): 907–913.
https://doi.org/10.1158/1078-0432.CCR-08-2251
Published: 02 February 2009
View article titled, Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with <em>MET</em> Amplification
Open the PDF for Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with <em>MET</em> Amplification in another window
Journal Articles

Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers

Kimio Yonesaka, Kreshnik Zejnullahu, Neal Lindeman, Alison J. Homes, David M. Jackman, Feng Zhao, Andrew M. Rogers, Bruce E. Johnson, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 6963–6973.
https://doi.org/10.1158/1078-0432.CCR-08-0957
Published: 03 November 2008
View article titled, Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <em>EGFR</em> Wild-type Cancers
Open the PDF for Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <em>EGFR</em> Wild-type Cancers in another window
Includes: Supplementary data
Journal Articles

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

Daniel B. Costa, Kim-Son H. Nguyen, Byoung C. Cho, Lecia V. Sequist, David M. Jackman, Gregory J. Riely, Beow Y. Yeap, Balázs Halmos, Joo H. Kim, Pasi A. Jänne, Mark S. Huberman, William Pao, Daniel G. Tenen, Susumu Kobayashi
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7060–7067.
https://doi.org/10.1158/1078-0432.CCR-08-1455
Published: 03 November 2008
View article titled, Effects of Erlotinib in <em>EGFR</em> Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Open the PDF for Effects of Erlotinib in <em>EGFR</em> Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib in another window
Journal Articles

Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer

Luca Toschi, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19): 5941–5946.
https://doi.org/10.1158/1078-0432.CCR-08-0071
Published: 30 September 2008
View article titled, Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer
Open the PDF for Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer in another window
Journal Articles

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Jussi P. Koivunen, Craig Mermel, Kreshnik Zejnullahu, Carly Murphy, Eugene Lifshits, Alison J. Holmes, Hwan Geun Choi, Jhingook Kim, Derek Chiang, Roman Thomas, Jinseon Lee, William G. Richards, David J. Sugarbaker, Christopher Ducko, Neal Lindeman, J. Paul Marcoux, Jeffrey A. Engelman, Nathanael S. Gray, Charles Lee, Matthew Meyerson, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (13): 4275–4283.
https://doi.org/10.1158/1078-0432.CCR-08-0168
Published: 01 July 2008
View article titled, <em>EML4-ALK</em> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Open the PDF for <em>EML4-ALK</em> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?

Myung-Ju Ahn, Byeong-Bae Park, Jin Seok Ahn, Sang We Kim, Heung-Tae Kim, Jong Seog Lee, Jin Hyung Kang, Jae Yong Cho, Hong Suk Song, Se Hoon Park, Chang Hak Sohn, Sang Won Shin, Jin Hyuck Choi, Chang-Seok Ki, Chan Keum Park, Alison J. Holmes, Pasi A. Jänne, Keunchil Park
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3860–3866.
https://doi.org/10.1158/1078-0432.CCR-07-4608
Published: 16 June 2008
View article titled, Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?
Open the PDF for Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer? in another window
Journal Articles

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

Jeffrey A. Engelman, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (10): 2895–2899.
https://doi.org/10.1158/1078-0432.CCR-07-2248
Published: 15 May 2008
View article titled, Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
Open the PDF for Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer in another window
Journal Articles

Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer

Bruce E. Johnson, David Jackman, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (15): 4628s–4631s.
https://doi.org/10.1158/1078-0432.CCR-07-0717
Published: 01 August 2007
View article titled, Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer
Open the PDF for Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer in another window
Journal Articles

Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients

Lecia V. Sequist, Victoria A. Joshi, Pasi A. Jänne, Daphne W. Bell, Panos Fidias, Neal I. Lindeman, David N. Louis, Jeffrey C. Lee, Eugene J. Mark, Janina Longtine, Peter Verlander, Raju Kucherlapati, Matthew Meyerson, Daniel A. Haber, Bruce E. Johnson, Thomas J. Lynch
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4403s–4408s.
https://doi.org/10.1158/1078-0432.CCR-06-0099
Published: 20 July 2006
View article titled, <em>Epidermal Growth Factor Receptor</em> Mutation Testing in the Care of Lung Cancer Patients
Open the PDF for <em>Epidermal Growth Factor Receptor</em> Mutation Testing in the Care of Lung Cancer Patients in another window
Journal Articles

Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Pasi A. Jänne, Bruce E. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4416s–4420s.
https://doi.org/10.1158/1078-0432.CCR-06-0555
Published: 20 July 2006
View article titled, Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Open the PDF for Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in another window
Journal Articles

Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

Bruce E. Johnson, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4436s–4440s.
https://doi.org/10.1158/1078-0432.CCR-06-0629
Published: 20 July 2006
View article titled, Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer
Open the PDF for Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer in another window
Journal Articles

Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

Thomas J. Lynch, Alex A. Adjei, Paul A. Bunn, Jr., Tim G. Eisen, Jeffrey Engelman, Glenwood D. Goss, Daniel A. Haber, John V. Heymach, Pasi A. Jänne, Bruce E. Johnson, David H. Johnson, Rogerio C. Lilenbaum, Matthew Meyerson, Alan B. Sandler, Lecia V. Sequist, Jeffrey Settleman, Kwok-Kin Wong, Carol S. Hart
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4365s–4371s.
https://doi.org/10.1158/1078-0432.CCR-06-1005
Published: 20 July 2006
View article titled, Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents
Open the PDF for Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents in another window
Journal Articles

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

David M. Jackman, Beow Y. Yeap, Lecia V. Sequist, Neal Lindeman, Alison J. Holmes, Victoria A. Joshi, Daphne W. Bell, Mark S. Huberman, Balazs Halmos, Michael S. Rabin, Daniel A. Haber, Thomas J. Lynch, Matthew Meyerson, Bruce E. Johnson, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (13): 3908–3914.
https://doi.org/10.1158/1078-0432.CCR-06-0462
Published: 03 July 2006
View article titled, Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
Open the PDF for Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib in another window
Journal Articles

A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening

Pasi A. Jänne, Ana M. Borras, Yanan Kuang, Andrew M. Rogers, Victoria A. Joshi, Hema Liyanage, Neal Lindeman, Jeffrey C. Lee, Balazs Halmos, Elizabeth A. Maher, Robert J. Distel, Matthew Meyerson, Bruce E. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (3): 751–758.
https://doi.org/10.1158/1078-0432.CCR-05-2047
Published: 07 February 2006
View article titled, A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening
Open the PDF for A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening in another window
Journal Articles

Inhibition of the Met Receptor in Mesothelioma

Toru Mukohara, Gabriel Civiello, Ian J. Davis, Michele L. Taffaro, James Christensen, David E. Fisher, Bruce E. Johnson, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (22): 8122–8130.
https://doi.org/10.1158/1078-0432.CCR-05-1191
Published: 18 November 2005
View article titled, Inhibition of the Met Receptor in Mesothelioma
Open the PDF for Inhibition of the Met Receptor in Mesothelioma in another window
Journal Articles

Prospective Study of the Airways and Pulmonary Parenchyma of Patients at Risk for a Second Lung Cancer

Melissa Means-Markwell, R. Ilona Linnoila, John Williams, Pasi A. Jänne, Frederic Kaye, Kevin O’Neil, Bruce E. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (16): 5915–5921.
Published: 15 December 2003
View article titled, Prospective Study of the Airways and Pulmonary Parenchyma of Patients at Risk for a Second Lung Cancer
Open the PDF for Prospective Study of the Airways and Pulmonary Parenchyma of Patients at Risk for a Second Lung Cancer in another window
Journal Articles

Induction Docetaxel and Carboplatin Followed by Weekly Docetaxel and Carboplatin with Concurrent Radiotherapy, then Surgery in Stage III Non-Small Cell Lung Cancer: A Phase I Study

Lori J. Wirth, Joan Lucca, Patricia Ostler, Panos Fidias, Cathy Lynch, Pasi A. Jänne, Roy S. Herbst, Bruce E. Johnson, David J. Sugarbaker, Douglas J. Mathisen, Jeanne M. Lukanich, Noah C. Choi, Stuart M. Berman, Arthur T. Skarin
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (5): 1698–1704.
Published: 01 May 2003
View article titled, Induction Docetaxel and Carboplatin Followed by Weekly Docetaxel and Carboplatin with Concurrent Radiotherapy, then Surgery in Stage III Non-Small Cell Lung Cancer: <subtitle>A Phase I Study</subtitle>
Open the PDF for Induction Docetaxel and Carboplatin Followed by Weekly Docetaxel and Carboplatin with Concurrent Radiotherapy, then Surgery in Stage III Non-Small Cell Lung Cancer: <subtitle>A Phase I Study</subtitle> in another window